{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:24:48Z","timestamp":1790220288890,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,12,8]],"date-time":"2003-12-08T00:00:00Z","timestamp":1070841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,12,8]],"date-time":"2003-12-08T00:00:00Z","timestamp":1070841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,1,1]]},"DOI":"10.1038\/sj.bmt.1704329","type":"journal-article","created":{"date-parts":[[2003,12,8]],"date-time":"2003-12-08T10:12:03Z","timestamp":1070878323000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention"],"prefix":"10.1038","volume":"33","author":[{"given":"S","family":"Corbacioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Dilloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Strahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Gross-Wieltsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K W","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ridolfi-L\u00fcthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Mihatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,12,8]]},"reference":[{"key":"BF1704329_CR1","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005\u20133020.","journal-title":"Blood"},{"key":"BF1704329_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BF1704329_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/00043426-200212000-00013","volume":"24","author":"U Reiss","year":"2002","unstructured":"Reiss U, Cowan M, McMillan A, Horn B . Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746\u2013750.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BF1704329_CR4","first-page":"53","volume":"3","author":"L Brugieres","year":"1988","unstructured":"Brugieres L, Hartmann O, Benhamou E et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 1988; 3: 53\u201358.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00688324","volume":"37","author":"G Vassal","year":"1996","unstructured":"Vassal G, Koscielny S, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247\u2013253.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1704329_CR6","first-page":"135","volume":"10","author":"V Meresse","year":"1992","unstructured":"Meresse V, Hartmann O, Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135\u2013141.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.bmt.1701506","volume":"22","author":"S Hasegawa","year":"1998","unstructured":"Hasegawa S, Horibe K, Kawabe T et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22: 1191\u20131197.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.bmt.1703393","volume":"29","author":"B Horn","year":"2002","unstructured":"Horn B, Reiss U, Matthay K et al. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002; 29: 409\u2013415.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","volume":"64","author":"E Carreras","year":"2000","unstructured":"Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281\u2013291.","journal-title":"Eur J Haematol"},{"key":"BF1704329_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","volume":"11","author":"JP Radich","year":"1993","unstructured":"Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304\u2013313.","journal-title":"J Clin Oncol"},{"key":"BF1704329_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.510290609","volume":"29","author":"SI Strasser","year":"1999","unstructured":"Strasser SI, Myerson D, Spurgeon CL et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893\u20131899.","journal-title":"Hepatology"},{"key":"BF1704329_CR12","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood.V87.5.2082.2082","volume":"87","author":"G Lucarelli","year":"1996","unstructured":"Lucarelli G, Clift RA, Galimberti M et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87: 2082\u20132088.","journal-title":"Blood"},{"key":"BF1704329_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM199002153220701","volume":"322","author":"G Lucarelli","year":"1990","unstructured":"Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417\u2013421.","journal-title":"N Engl J Med"},{"key":"BF1704329_CR14","doi-asserted-by":"publisher","first-page":"415a","DOI":"10.1182\/blood-2002-01-0011","volume":"100","author":"SL Goldberg","year":"2002","unstructured":"Goldberg SL, Ellent D, Shtrambrand D et al. Gemtuzumab ozogamicin (mylotarg) prior to allogeneic hematopoietic stem cell transplantation increases the risk of hepatic veno-occlusive disease. Blood 2002; 100: 415a.","journal-title":"Blood"},{"key":"BF1704329_CR15","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi P, Shulman HM, Sievers EL et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310\u20132314.","journal-title":"Blood"},{"issue":"Suppl. 11","key":"BF1704329_CR16","first-page":"191a","volume":"98","author":"T Martin","year":"2001","unstructured":"Martin T, Shahjahan M, de Lima M et al. The use of Mylotarg as anti-leukemia therapy increases the incidence of liver toxicity including VOD following allogeneic transplantation. Blood 2001; 98 (Suppl. 11): 191a.","journal-title":"Blood"},{"issue":"Suppl. 11","key":"BF1704329_CR17","first-page":"124a","volume":"98","author":"EA Stadtmauer","year":"2001","unstructured":"Stadtmauer EA, Larson R, Sievers E et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with Gemtuzumab Ozagamicin (Mylotarg, CMA-676). Blood 2001; 98 (Suppl. 11): 124a.","journal-title":"Blood"},{"key":"BF1704329_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/sj.bmt.1703242","volume":"28","author":"DK Tack","year":"2001","unstructured":"Tack DK, Letendre L, Kamath PS et al. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 2001; 28: 895\u2013897.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR19","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578\u20131582.","journal-title":"Blood"},{"key":"BF1704329_CR20","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood.V99.9.3458","volume":"99","author":"AS Schulz","year":"2002","unstructured":"Schulz AS, Classen CF, Mihatsch WA et al. HLA-haploidentical blood progenitor cell transplantation in osteopetrosis. Blood 2002; 99: 3458\u20133460.","journal-title":"Blood"},{"key":"BF1704329_CR21","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599\u20133604.","journal-title":"Blood"},{"key":"BF1704329_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","volume":"45","author":"KJ Palmer","year":"1993","unstructured":"Palmer KJ, Goa KL . Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993; 45: 259\u2013294.","journal-title":"Drugs"},{"issue":"Suppl. 10","key":"BF1704329_CR23","first-page":"148a","volume":"94","author":"A Falanga","year":"1999","unstructured":"Falanga A, Marchetti M, Vignoli A et al. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood 1999; 94 (Suppl. 10): 148a.","journal-title":"Blood"},{"issue":"Suppl. 11","key":"BF1704329_CR24","first-page":"53a","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Vignoli A et al. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cells from macro- and micro-vessles. Blood 2000; 96 (Suppl. 11): 53a.","journal-title":"Blood"},{"key":"BF1704329_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood.V100.1.334","volume":"100","author":"G Eissner","year":"2002","unstructured":"Eissner G, Multhoff G, Gerbitz A et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100: 334\u2013340.","journal-title":"Blood"},{"key":"BF1704329_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/10428199809059219","volume":"31","author":"P Richardson","year":"1998","unstructured":"Richardson P, Bearman SI . Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998; 31: 267\u2013277.","journal-title":"Leuk Lymphoma"},{"key":"BF1704329_CR27","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","volume":"111","author":"R Chopra","year":"2000","unstructured":"Chopra R, Eaton JD, Grassi A et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122\u20131129.","journal-title":"Br J Haematol"},{"key":"BF1704329_CR28","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Murakami C, Jin Z et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100: 4337\u20134343.","journal-title":"Blood"},{"key":"BF1704329_CR29","first-page":"112a","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Soiffer R, Antin JH et al. Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). Blood 2002; 100: 112a.","journal-title":"Blood"},{"key":"BF1704329_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778\u2013783.","journal-title":"Transplantation"},{"key":"BF1704329_CR31","first-page":"197","volume":"10","author":"HM Shulman","year":"1992","unstructured":"Shulman HM, Hinterberger W . Hepatic veno-occlusive disease \u2013 liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197\u2013214.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","volume":"89","author":"SI Bearman","year":"1997","unstructured":"Bearman SI, Lee JL, Baron AE et al. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501\u20131506.","journal-title":"Blood"},{"key":"BF1704329_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/sj.bmt.1701654","volume":"23","author":"S Kulkarni","year":"1999","unstructured":"Kulkarni S, Rodriguez M, Lafuente A et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999; 23: 803\u2013807.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/sj.bmt.1703881","volume":"31","author":"RP Bajwa","year":"2003","unstructured":"Bajwa RP, Cant AJ, Abinun M et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 2003; 31: 591\u2013597.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR35","first-page":"439","volume":"5","author":"TP Baglin","year":"1990","unstructured":"Baglin TP, Harper P, Marcus RE . Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5: 439\u2013441.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR36","first-page":"737","volume":"92","author":"PG Richardson","year":"1998","unstructured":"Richardson PG, Elias AD, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737\u2013744.","journal-title":"Blood"},{"key":"BF1704329_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF01695888","volume":"66","author":"E Carreras","year":"1993","unstructured":"Carreras E, Granena A, Navasa M et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66: 77\u201380.","journal-title":"Ann Hematol"},{"key":"BF1704329_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2141.1990.tb02583.x","volume":"74","author":"E Gluckman","year":"1990","unstructured":"Gluckman E, Jolivet I, Scrobohaci ML et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277\u2013281.","journal-title":"Br J Haematol"},{"key":"BF1704329_CR39","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","volume":"79","author":"M Attal","year":"1992","unstructured":"Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834\u20132840.","journal-title":"Blood"},{"key":"BF1704329_CR40","first-page":"185","volume":"18","author":"J Rosenthal","year":"1996","unstructured":"Rosenthal J, Sender L, Secola R et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 18: 185\u2013191.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/(SICI)1096-8652(199609)53:1<46::AID-AJH11>3.0.CO;2-1","volume":"53","author":"R Or","year":"1996","unstructured":"Or R, Elad S, Shpilberg O et al. Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients. Am J Hematol 1996; 53: 46\u201348.","journal-title":"Am J Hematol"},{"key":"BF1704329_CR42","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","volume":"27","author":"M Simon","year":"2001","unstructured":"Simon M, Hahn T, Ford LA et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27: 627\u2013633.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","volume":"64","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Tanabe J, Watanabe R et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32\u201338.","journal-title":"Am J Hematol"},{"key":"BF1704329_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","volume":"128","author":"JH Essell","year":"1998","unstructured":"Essell JH, Schroeder MT, Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975\u2013981.","journal-title":"Ann Intern Med"},{"key":"BF1704329_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","volume":"29","author":"SH Park","year":"2002","unstructured":"Park SH, Lee MH, Lee H et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137\u2013143.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704329_CR46","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","volume":"100","author":"T Ruutu","year":"2002","unstructured":"Ruutu T, Eriksson B, Remes K et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977\u20131983.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1038\/sj.bmt.1704494","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2004,3,8]],"date-time":"2004-03-08T00:00:00Z","timestamp":1078704000000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704329","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:58:38Z","timestamp":1648079918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,1,1]]}},"alternative-id":["BF1704329"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704329","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/sj.bmt.1704494","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,8]]},"assertion":[{"value":"10 June 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}